A new Biopharma Sentiment Index update reported a rebound in headline conditions during Q2 2026, with the overall score rising to 96 from 90 in Q1. The measure also showed hiring resilience and improved views on current operations, while future expectations on funding softened. The report highlighted that less than half the ecosystem appears prepared for policy and regulatory shifts, and that the 12-month outlook for fundraising fell 13 points, returning funding expectations to negative territory. For biotech strategists, the data suggests near-term optimism is constrained by continued uncertainty around capital availability and regulatory conditions that affect trial and commercialization planning.